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ABSTRACT 
Ischemia-modified albumin has been investigated for use in human medicine as a clinical marker 
of ischemia, with particular interest geared toward detecting patients that have chest pain due to 
coronary artery syndrome. The modified form of circulating albumin has a decreased ability to 
bind transition metals, and assays are available that measure the amount of cobalt and nickel that 
bind to albumin in vitro. Oxidative damage has long been a suspected component of the 
underlying mechanism, while more recent work suggests that increased free fatty acid binding to 
albumin may also play a role in altering the albumin molecule binding characteristics. 
This study validated a cobalt-binding assay for use in cats. Percent cobalt binding (%CB) of 
serum was assessed. The run-to-run coefficient of variation ranged from 2.90% to 4.37%, while 
within-run precision had a coefficient of variation that ranged from 2.61% to 4.04%. Day-to-day 
precision was 3.46%. Limited assessment of biological variation revealed minimal change. Up to 
three freeze-thaw cycles failed to induce clinically significant variation in cobalt binding 
percentages in most samples. Samples appeared stable for at least 4 hours at room temperature. 
Addition of conjugated bilirubin to serum was tested up to a total bilirubin concentration of 8.9 
mg/dL (icteric index of 2+) and failed to have a clinically significant effect on the percent cobalt 
binding; however, severely hemolytic (≥4+) samples and even mildly lipemic (≥1+) samples 
were falsely decreased in the percent cobalt binding when compared to the unadulterated original 
sample. Overall, this assay appears to function reasonably well in the measurement of cobalt-
binding albumin in feline serum.  
Percent cobalt binding of serum from healthy and diseased cats was assessed for significant 
physiological and pathophysiological correlations. It did not correlate with age, sex, or breed in 
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the study population. Unsurprisingly, %CB was correlated with albumin concentration (r= 0.62, 
p=0.0001). Other noted correlations included red blood cell count (r= 0.24, p=0.003), 
hemoglobin (r= 0.29, p=0.0001), hematocrit (r= 0.283, p=0.0001), globulins (r= -0.20, p=0.01), 
calcium (r= 0.27, p=0.001), total bilirubin (r= -0.237, p=0.005), and absolute lymphocytes (r= 
0.16, p=0.05). However, the albumin concentration was decreased in the inflammatory group, in 
comparison with the noninflammatory group, and, likewise, albumin was correlated with red 
blood cell count, hemoglobin, hematocrit, globulins, calcium, and total bilirubin. The only 
parameter to which %CB seemed independently linked was a very weak correlation to the 
absolute lymphocyte count. Percent cobalt binding and albumin concentration were decreased in 
cases classified as ―inflammatory‖, as compared with those classified as ―noninflammatory‖. 
While %CB was not correlated with any of the disease categories of this study, group numbers 
were small.  
Limitations of this study included variable sample handling, small disease group numbers, and 
retrospective evaluation. The consistency of the relationship between albumin concentrations, 
albumin-linked correlates, and the measured %CB seems to confirm the validity of the assay in 
measuring ischemia-modified albumin, though this study failed to show a definitive clinical 
relevance of the assay in cats. Prospective studies with more controlled sample handling may 
yield more clinically significant findings. 
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CHAPTER 1 
INTRODUCTION 
In human medicine, there has been interest in developing biomarkers that can detect myocardial 
ischemia in patients with chest pain, ideally, prior to complete infarction. One proposed 
biomarker is the ischemia modified albumin (IMA) test, a colorimetric assay that utilizes patient 
serum to indirectly measure changes in the ability of albumin to reversibly bind ionized cobalt. 
An assay for IMA, the Albumin Cobalt Binding test, was approved by the Food and Drug 
Administration (FDA) in 2003
1
. Studies conducted over the past decade have shown that other 
conditions, including strenuous exercise, diabetes mellitus, and obesity, also have the potential to 
reduce albumin-cobalt binding
2–6
.  While it is likely that there are multiple mechanisms for 
altered serum cobalt binding with ischemia and other conditions, it is believed that free radical 
damage to the transition metal binding sites of albumin inhibits the protein‘s ability to reversibly 
bind to transition metals, such as cobalt
7
. Increased serum free fatty acid concentrations may also 
competitively inhibit cobalt binding by albumin
8
. However, the mechanism for altered albumin-
cobalt binding with diseasesis incompletely characterized at this time. 
With the exception of limited studies utilizing laboratory animals (rabbits and rats) as 
experimental models of ischemia in various tissues
9–12
, serum cobalt binding has not been 
assessed in veterinary species. It is unknown whether this marker is measurable in common 
companion animal species, such as cats, dogs, and horses, and if such a marker would hold any 
value in diagnostic testing and medical decision-making. Therefore, this study was undertaken to 
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validate and investigate serum cobalt binding in domestic cats, in order to evaluate for potential 
uses in veterinary medicine. 
Between June 2011 and December 2011, residual serum from samples submitted to the 
University of Illinois Clinical Pathology Laboratory was collected and assayed for percent cobalt 
binding (%CB). The samples were from cats, presented to the Veterinary Teaching Hospital for 
any reason during the study period, in which diagnostic testing on serum was part of the medical 
work up. The specific diagnostic testing was requested by the clinician on the case, and the 
author was blinded to the testing performed on the samples by the clinical pathology lab until 
after cobalt binding assays were complete. All serum samples submitted during the study period 
were considered for inclusion in the study. 
Validation testing revealed that the assay successfully measures serum cobalt binding in cats. 
Within-run precision ranged from 2.61 to 4.04% over 24 runs. Run-to-run precision was ranged 
from 2.90 to 4.37% over 30 runs (3 samples, 10 runs each). Day-to-day precision was 3.46% 
over 5 days. Limited biological variation assessment showed clinically insignificant changes. 
Serial dilutions (1: 2, 1: 4, and 1: 8) were linear. Temperature stability testing and freeze-thaw 
stability were assessed for clinically significant changes in percent cobalt binding, defined by the 
author as a change greater than 10% from the baseline value. Samples were found to be stable 
with up to three freeze-thaw cycles, while most samples did not vary more than 10% from 
baseline up to 4 hours after sample collection while at room temperature. Assessment for effects 
of interfering substances revealed that up to 8.9 mg/dL of conjugated bilirubin (2+ icteric index) 
failed to have a significant effect on %CB, while a 1+ lipemic index or greater and 4+ hemolytic 
index had negative effects on %CB.  
3 
 
Of 374 samples initially collected, 175 were of sufficient volume and quality to be included in 
the study. The median %CB was 73.9% (25-75
th
 percentiles: 66.2-80.3%, min-max: 34.93-
92.37%). Cobalt binding values were not found to be significantly different by disease state, sex, 
age, or breed. Cobalt binding was found to be positively correlated with red blood cell count 
(r=0.24, p=0.003), hemoglobin (r=0.29, p=0.0001), hematocrit (r=0.283, p=0.0001), albumin 
(r=0.62, p=0.0001), total calcium (r=0.27, p=0.001), and absolute lymphocytes (r=0.16, p=0.05). 
Cobalt binding was negatively correlated with globulins (r= -0.20, p=0.01) and total bilirubin (r= 
-0.237, p=0.005). Cobalt binding was not correlated to white blood cell count, absolute 
segmented neutrophils, absolute band neutrophils, absolute monocytes, absolute eosinophils, 
absolute basophils, serum total protein, glucose, alkaline phosphatase (ALP), cholesterol, 
triglycerides, or corrected calcium. Because the correlation between albumin and %CB was the 
strongest of those observed, albumin was then evaluated for correlations with the other analytes 
described above. Absolute lymphocytes appeared to be the only analyte in which %CB was 
correlated, independent of albumin. The reason for this is uncertain, and the clinical significance 
of this weak correlation is likely negligible. Cats characterized as having inflammation (n=20) 
had significantly lower (p=0.002) cobalt binding percentages than cats without evidence of 
inflammation (n=22). The albumin concentration of the cats in the inflammatory group also had 
an albumin concentration that was significantly lower than that of the noninflammatory group. 
Because albumin is a negative acute phase protein, this is a logicalexplanation for the apparent 
%CB correlation to inflammation in this study. 
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CHAPTER 2 
LITERATURE REVIEW 
Albumin is the most abundant protein in plasma and is synthesized by the liver. It provides 
colloid oncotic pressure and is a carrier for many substances, including fatty acids, bile acids, 
bilirubin, hormones, vitamins, calcium, and transition metals, including copper(II), nickel(II), 
cadmium(II) and cobalt(II)
13
. The half-life of albumin in people varies from15-23 days
14
, 
although a narrower range is sometimes used
15,16
. The half-life of feline serum albumin does not 
seem to have been described, but it is reported as 8.2 days in dogs
17
. Human serum albumin is 
585 residues, made up of 3 homogenous domains
18,19
, while feline serum albumin is reported to 
be 584 residues
20
. The proteins appear 81% homologous, with similar amino-terminus residues; 
human albumin is Asp-Ala-His, while feline albumin is Glu-Ala-His (Figure 1).  
The ability of albumin to bind transition metals, in particular Co(II), is the focus of this study and 
relevant principles will be reviewed here. Free Cu(II) ions and Fe(III) salts can generate free 
radicals via the Fenton reaction
21
, so the ability of albumin to bind transition metal ions serves a 
protective role. Three binding sites for cobalt have been defined through spectroscopic and 
thermodynamic experiments; in order of decreasing affinity, these are the carboxylate-rich 
cadmium site B (site B), the multi-metal binding site (MBS or site A), and the amino-terminal 
binding site (NTS)
18
. Chan et al. found that human serum albumin incubated in vitro at 4
o
C and 
37
o
C for 12 days experienced degradation of the Asp-Ala residues, released as a dipeptide of the 
NTS, but this did not appear to be due to transition metal binding itself
22
. For a long period, the 
NTS was thought to be the only or the primary binding site for cobalt, and it was theorized that 
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this site could become damaged by free radicals secondary to ischemia and/or reperfusion 
injury
23
. The study by Chan was used as support for the susceptibility of the NTS to 
degradation
23
, though the cause of the in vitro degradation in that study was not determined. 
Interestingly, that study did not find similar degradation with bovine, chicken, dog, goat, horse, 
pig, rabbit, rat, or sheep albumin. Cat albumin was not tested, though the three terminal NTS 
residues matched those of rat and rabbit albumin (Glu-Ala-His); however the next two residues 
in sequence differed from those species‘ albumin (-Gln-Ser vs. -Lys-Ser)20,22. 
An assay has been described
7,23
 that measures the cobalt binding ability of a serum sample. It 
works by adding a known amount of Co(II) to a solution containing patient serum albumin. 
Normally, albumin binds a given quantity of the cobalt, leaving a small amount free in the 
medium. Dithiothreitol (DTT) is then added, which reacts with the free cobalt to produce a color 
change; this is subsequently measured spectrophotometrically. In patients experiencing ischemia, 
an increased fraction of the serum albumin has a decreased ability to bind the cobalt. This 
ischemia-modified albumin leaves increased amounts of free cobalt in solution, which 
consequently reacts with more DTT, producing a darker color change and a higher reading of 
absorbance units (ABSU); in the literature, this indirect measurement is then reported as the 
value of IMA in patients. Figure 2 is a cartoon illustrating the assay. 
In 2000, Bar-Or et al. published a paper on the assay, terming it the albumin cobalt binding 
(ACB) assay
23
. The authors investigated the results of this assay as an early marker of 
myocardial ischemia. The goal was to develop a biomarker that would improve the ability to 
detect myocardial ischemia in patients presenting for chest pain due to cardiac causes
23
. This 
early study found that ACB values from a group of patients diagnosed with acute myocardial 
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ischemia were higher than those of patients that presented with chest pain due to noncardiac 
causes. The altered albumin came to be known as ischemia modified albumin (IMA). Further 
work in cardiac patients followed, as well as evaluation of the assay in other diseases. Evaluation 
of IMA levels in patients undergoing percutaneous coronary intervention (angioplasty), in which 
a balloon is inserted into a narrowed artery and inflated, found that this procedure causes an 
immediate rise in IMA, which resolves quickly after the procedure is over
24–27
. Results returned 
to normal by 1 hour post-procedure
26
. Garrido et al. found that IMA increased with angioplasty 
in patients with unstable angina, but there was less of an increase in patients that had collateral 
coronary circulation, compared with those that did not
28
. In one study, IMA was increased 
immediately after the procedure and was normal by 6 hours, while creatine kinase-MB, 
myoglobin, and cardiac troponin I were normal immediately after and increased at 6 hours, 
supporting IMA as an early marker of ischemia, with an advantage over more conventional 
markers
27
. Some researchers found weak correlations between IMA increase and the pressure 
and duration of balloon inflation
25
, but others did not
29
. IMA was also found to increase 30 
minutes after cross-clamping of vessels in cardiac bypass surgery, decreasing in the 6 hours post-
operatively but not returning to the pre-operative baseline
30
. Through the progression of research, 
it appeared that there was a strong relationship between ischemia and the development of 
increased proportions of IMA in circulation.  
In addition to myocardial ischemia, increases in IMA have been found in volunteers 
experiencing skeletal muscle ischemia, in patients with conditions associated with oxidative 
stress, such as diabetes mellitus and obesity, in experimental models of organ torsion, in patients 
with thromboembolic disease, and in pregnant women, among others
3,10,11,31–34
. Several reviews 
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have also been published
15,35–39
. The only published studies to date regarding serum cobalt 
binding and IMA in veterinary species have been in experimental models utilizing laboratory 
animals. These will be outlined below with related studies. 
The exact mechanism of IMA formation remains unconfirmed. Despite initial interest in the 
amino terminus of albumin, a few studies have found that alteration of the NTS of albumin has 
little relationship to increasing IMA levels
40,41
, and recent studies have convincingly shown that 
there are three Co(II) binding sites
18,42
. This more recent work has indicated that cobalt affinity 
for the NTS is the lowest of the three sites. However, the early research on IMA and the ACB 
assay lacked this information, and the NTS was presumed to be the primary cobalt binding site 
and to be damaged in some way during the ischemia and/or reperfusion process. Oxidative 
damage by reactive oxygen species was one proposed mechanism, which found some support in 
an in vitro study that evaluated the effects of hydrogen peroxide, superoxide radical, and 
hydroxyl radical (generated via Fenton reaction) on human serum albumin
7
. Hydrogen peroxide 
and superoxide radical treatment were found to have negligible effects on IMA, but hydroxyl 
generation by the Fenton reaction with Cu(II) increased IMA up to 43.6% after 15 minutes. 
Another study found similar in vitro results, supporting the importance of the Fenton reaction 
and hydroxyl radical generation in causing a decrease in albumin cobalt binding
43
. Studies in 
people have found some peripheral support for oxidative damage, likely secondary to 
inflammation, as a mechanism of IMA formation. Several have found IMA and C-reactive 
protein (CRP, a nonspecific marker of inflammation) both to be increased in patients
4,5,44–49
. 
While some did not report correlation information
4,44,46,49
, others reported a correlation between 
IMA and CRP
5,45,48
, while one found no link
47
. Others found indirect evidence of oxidative 
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damage via increases in malondialdehyde
32,50–53
, homocysteine
49,52
, protein carbonyl
53,54
, and 
advanced oxidation protein products
53
, though correlation information was not included. Two 
studies investigating ischemia in rat models found that administration of compounds with 
antioxidant properties (clotrimazole
55
 and N-acetylcysteine
56
) blunted increases in IMA 
following vessel ligation. 
Another theory that is gaining traction in the literature is that increased free fatty acid binding to 
albumin obscures the two primary binding sites for cobalt, resulting in increased levels of IMA
8
. 
Fatty acids are known to be increased during myocardial ischemia
57,58
. A study of IMA and fatty 
acid levels compared patients with acute myocardial infarction to a control group (in which 
patients with renal disease, thyroid disease, diabetes mellitus, obesity, and patients with albumin 
concentrations outside the reference interval were excluded)
57
. They found that IMA and fatty 
acids were increased and correlated in patients with myocardial infarction; further evaluation 
determined that oleic, palmitic, linoleic, stearic, and palmitoleic acids were increased, while 
arachidonic acid was not. They went on to perform in vitro experiments on pooled serum to 
further test the association. The addition of oleate and arachidonate in vitro was found to increase 
the IMA levels, and the authors concluded that alterations in fatty acid binding to albumin were 
the source of increased IMA in patients with myocardial infarction. Another study that extracted 
fatty acids bound to the albumin of patients with fatty liver and normal controls found that fatty 
liver patients had increased amounts of oleic, myristic, and lauric acid and that this influenced 
cobalt binding to albumin
43
. Finally, a recent in vitro study further evaluated the relationship 
between fatty acids and cobalt binding. The fatty acid myristate was added to bovine serum 
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albumin solutions in increasing concentrations and cobalt binding was assayed. With increasing 
myristate concentrations, cobalt binding decreased progressively
8
.  
Unfortunately, the studies above make up the few that have reported fatty acid concentrations 
with IMA results. Of published reports that include other patient lipid information, triglyceride, 
total cholesterol, high density lipoprotein (HDL) cholesterol, and low density lipoprotein (LDL) 
cholesterol concentrations are those most commonly reported, and results have been variable. A 
study of patients with myocardial infarction found no correlation between IMA levels and total 
cholesterol
45
. Similarly, Kaefer et al., in a study of diabetic patients, found that IMA was not 
correlated to triglycerides, total cholesterol, or HDL cholesterol
5
. In contrast, a study of patients 
with hyperthyroidism or hypothyroidism found that, along with increased IMA, hypothyroid 
patients had increased total, HDL and LDL cholesterol levels, though none was correlated with 
IMA. Hyperthyroid patients, on the other hand, were found to have increased IMA and decreased 
total and LDL cholesterol concentrations, and both were negatively correlated with IMA. 
Regardless of the mechanism of IMA formation, the overall albumin concentration has been 
shown to be an important factor in the IMA result
59–62
, often the only or strongest correlate—a 
link that is unsurprising. It is logical that IMA is negatively correlated with albumin 
concentrations, since a serum sample with a low albumin concentration would appear to have an 
increased IMA level—fewer albumin molecules would be present to bind the standardized 
amount of cobalt added during the cobalt binding assay, resulting in an increased amount of free 
cobalt and a darker colorimetric result. The negative correlation between the two factors was 
found to be strongest when hypoalbuminemia was present
63
, a fact that could limit the utility of 
the cobalt binding assay
64
.  
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To combat this limiting factor, several authors have proposed correction formulas or ratios to 
normalize a sample for the albumin concentration. In a study of patients presenting to the 
emergency department, use of an albumin-adjusted IMA index had an improved sensitivity 
(98.4%) for ruling out acute coronary syndrome compared with IMA (93.0%)
65
. The formula 
used was: [albumin-adjusted IMA index = serum albumin concentration (g/dL) x 23 + IMA 
(U/mL) – 100]. Another group calculated an IMA value adjusted for albumin via the following 
formula: [(individual serum albumin concentration/median albumin concentration of the 
population) x IMA value]
62
. Using this, the median value increased only slightly (94 kU/L vs. 93 
kU/L), while the range narrowed from 62-135 to 69-110 kU/L, and the inter-individual 
coefficient of variation decreased from 15.4% to 10.0%. Another study used an IMA-to-serum 
albumin ratio (IMAR) in comparison with IMA in patients with chronic liver disease
66
. This was 
calculated by dividing IMA by the concentration of albumin in g/dL. Use of the IMAR allowed 
correlation to the model of end-stage liver disease (MELD) score and the Child-Turcotte-Pugh 
(CTP) score, which were not significant with IMA. The CTP score is used as an assessment of 
liver function, while the MELD score is used as a predictor of outcome
66
. However, none of 
these calculations appear to have been independently validated for use. 
Sample storage stability testing has been performed and published, with some variability of 
results between authors. A report validating the ACB assay on the Cobas MIRA Plus analyzer 
found that separated serum samples stored in open tubes at 4
o
C and 26
o
C displayed an increase 
of 3.0% and 5.7% at 4.5 hours after sample collection and a 7.9% and 13.0% increase, 
respectively, at 8.5 hours
67
. They also found that samples stored in closed tubes with the clot at 
26
o
C for 8.5 hours showed a 10.8% decrease in values. Another author found that samples stored 
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at 4
o
C and 26
o
C showed a 6.37% and 3.38% increase, respectively, at 2 hours after the baseline 
assay, while at 4 hours, the room temperature sample was increased 30% from baseline and the 
4
o
C sample was up 21%
68
. Another portion of that study compared sample storage on gel serum 
separator tubes and aliquoted samples in plain glass tubes. Interestingly, the increases with 
storage were less substantial here (with both storage techniques), compared with that described 
immediately above. At 4 hours, the samples stored on the serum separator gel increased 5.23%, 
while the aliquoted samples increased 9.24%. The authors of this study ultimately concluded that 
the samples were stable at both temperatures at least 2 hours but recommended assaying the 
sample within this time frame or freezing immediately to avoid any potential in vitro alterations.  
Samples appear relatively stable with freezing at -20
o
C. While Beetham and group found a 
statistically significant increase in assay results following thawing, it only amounted to an 
increase of 3.43%
69
, a difference that seems unlikely to have a strong influence in clinical 
decision-making. The Cobas MIRA paper found a 5% or less change in assay result with 
freezing at -20
o
C, with thawing at 4
o
C; however, a 15% increase was observed in samples 
thawed at room temperature
67
.  
The remainder of this review pertains to the clinical findings of IMA in particular diseases or 
conditions. In the majority of the studies, sample handling appears to have been relatively 
consistent. In many studies, the samples were frozen at -20
o
C or -80
o
C, though the period of 
freezing was variable and the temperature at which thawing occurred was not noted. 
Cardiac Disease 
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In human medicine, diagnosis of acute myocardial ischemia in patients presenting for chest pain 
can be challenging and typically relies on the combination of chest pain, changes on 
electrocardiogram (ECG), and serum marker elevation (such as cardiac troponins)
36
. However, 
markers like troponins T and I, while specific for cardiac injury
70
, are indicators of cell leakage 
or necrosis and therefore only become elevated once tissue damage has occurred. A reliable 
biomarker for early ischemia would be beneficial in minimizing cardiac damage
37
. Bar-Or and 
group noticed that in vitro binding of cobalt by serum from patients with myocardial ischemia 
was decreased and in 2000 published a paper describing the cobalt binding assay as a means of 
indirectly measuring ischemia-modified albumin, which they proposed as a biomarker of 
ischemia
23
. This initial study found that serum from patients with myocardial ischemia had 
greater amounts of unbound cobalt at the end of the assay, compared with patients without 
ischemia, suggesting that albumin was somehow stripped of its ability to bind cobalt in solution. 
The Albumin Cobalt Binding test was approved by the FDA in 2003 for use in ruling out 
myocardial ischemia, in combination with electrocardiogram and BNP testing
1
. This assay 
remains the only FDA-approved test for detecting ischemia.  
In the ensuing years, many studies have been carried out to test the ACB assay. Studies have 
primarily centered on cardiac conditions in which ischemia or infarction is the lesion of interest. 
Terminology used in the medical literature includes acute coronary syndrome (ACS), acute 
myocardial infarction/ischemia, unstable angina pectoris, and stable angina pectoris. Myocardial 
ischemia, the inadequate supply of oxygen to the heart, frequently is associated with partial 
obstruction of coronary vessels due to atherosclerosis and typically results in angina, or chest 
discomfort, in the patient
71
. Myocardial infarction is cardiac cell death following protracted 
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ischemia
72
. It is further subdivided according to the presence or absence of ST-segment elevation 
on ECG: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation 
myocardial infarction (NSTEMI)
72
. Stable angina pectoris is chest discomfort that occurs with 
exercise or emotional stress and resolves with rest, while unstable angina (UA) pectoris occurs at 
rest, as overt pain or as pain that increases in severity (―crescendo pattern‖)71. Unstable angina 
and NSTEMI are sometimes grouped together as one entity (―UA/NSTEMI‖)73. The use of the 
term ―acute coronary syndrome‖ throughout the medical literature appears to be used as a 
general reference to myocardial ischemia and infarction. According to Aparci et al., ACS 
includes unstable angina, NSTEMI, and STEMI
74
.  
The assays for IMA throughout the studies described below used manual or automated albumin 
cobalt binding assays, and automated assays were performed on one of several chemistry 
analyzers, though the Cobas MIRA analyzer seems to occur most frequently. IMA values are 
reported as absorbance units (ABSU). Optimal cut-offs or manufacturer cut-offs were used 
variously in determination of sensitivity and specificity. 
As referenced earlier, the use of IMA for early detection of myocardial ischemia (of any type) 
has been of interest to the medical community and a substantial body of literature investigating 
this now exists. Many studies have noted that IMA is increased in patients with myocardial 
ischemia, supporting the work of Bar-Or and group. Multiple studies have evaluated the 
sensitivity and specificity of IMA for myocardial ischemia, typically comparing patients with 
ischemic chest pain to those with non-ischemic chest pain. At an optimal cut-off value of 70.0 
units/mL, Liyan et al. reported a sensitivity of 94.4% and a specificity of 82.6% for detection of 
acute coronary syndrome in 113 patients. This study measured IMA within 12 hours of onset of 
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chest pain, and it also compared IMA performance to that of C-reactive protein (CRP). CRP only 
had a sensitivity of 70.0% and specificity of 73.9% for detection of ACS
44
. In a similar study, 
this group evaluated IMA again, this time comparing it to heart-fatty acid binding protein (H-
FABP), another potential marker of cardiac ischemia that is under review
75
. This study found 
that IMA sensitivity was 89% and specificity was 80.8% for ACS, while H-FABP was 82.9% 
sensitive and 80.8% specific. Combining the two markers improved sensitivity to 96.3%. The 
patients in this study had normal cardiac troponin concentrations upon presentation. 
Overall, other studies have had similar results, finding that, in patients with chest pain at 
presentation to the emergency department, IMA is moderately to very sensitive for myocardial 
ischemia, while specificity is moderate to poor. Sensitivity of IMA in studies similar to the two 
described above have ranged from 80% to 94.4%, while specificity has ranged from 31% to 
69%
76–78
. Interestingly, a rare study has found IMA to be very specific for myocardial ischemia. 
Bhagavan et al. reported a sensitivity of 88% and an impressive 94% specificity in distinguishing 
patients with myocardial ischemia from those without. However, when they tried to use IMA to 
determine acute versus non-acute myocardial infarction, IMA was not very useful, with an area 
under the ROC curve of only 0.66
41
.  
IMA has also been evaluated in conditions with vascular changes that precede chest pain due to 
ischemia. Koc et al. measured IMA in patients determined to have slow coronary flow due to 
stenosis of epicardial arteries and identified no increase
79
, while Kazanis et al. found IMA to be 
increased in patients that had atherosclerosis but no signs of acute coronary syndrome
80
. The 
latter study did not note any correlation between IMA levels and the number of diseased vessels. 
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Multiple studies have compared IMA to more established biomarkers, as well as evaluating the 
value of combining IMA with more standard tests to diagnose myocardial ischemia. As 
mentioned above, it has been shown that IMA was more sensitive and specific than CRP (a 
positive acute phase protein) and was more sensitive than H-FABP, with similar specificity, in 
identifying myocardial ischemia
44,75
. IMA alone was more sensitive than a panel of myoglobin, 
creatine kinase-MB, and cardiac troponin I, but addition of IMA to that panel resulted in a 
sensitivity of 97% and a negative predictive value of 92%
78
. For detection of ACS, ECG and 
cardiac troponin I (cTnI) had specificities of 91% and 99% respectively, but sensitivities of only 
45% and 20%, respectively. A panel of IMA, ECG, and cTnI resulted in an increased sensivity of 
95%. Collinson et al. found that in a study of patients suspected to have acute myocardial 
infarction, a normal cTnI result combined with a normal IMA result had a negative predictive 
value of 100%
81
. In 131 patients presenting with chest pain but with normal or non-diagnostic 
ECGs, IMA was higher in patients with ACS compared with those with nonischemic chest 
pain
82
. IMA had a sensitivity of 90.6% and specificity of 49.3% in classifying these patients. 
Sensitivity increased to 92.2% when combined with cardiac troponin T. From these described 
studies, it appears that IMA‘s value primarily lies in its ability to rule out ischemia, improving 
the performance of more standard diagnostic tests.  
A few studies have failed to find an advantage in the use of IMA assessment. A study of 185 
patients with NSTEMI did not find IMA to be predictive of ACS diagnosis [odds ratio (OR) = 
1.23; 95% CI = 0.87-1.81], while heart-fatty acid binding protein was predictive (OR = 4.65; 
95% CI = 2.39-9.04) and specific (96.8%)
83
. A study of 367 patients with chest pain found 
median IMA and ranges to be almost identical between the 162 patients with nonischemic chest 
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pain and the 205 patients with ischemic chest pain
39
. The reason for the similarity between 
groups in this study, in contrast with the findings of most other studies, is unknown. 
Several studies have evaluated IMA‘s predictive capabilities, though results describe limited 
utility in this capacity. A few have examined IMA‘s ability to predict a serious cardiac event 
(including death, myocardial infarction, heart failure, and arrhythmia) within 72 hours among 
patients presenting for chest pain. One study of 189 patients, of which 24 experienced serious 
outcomes within the study period, reported that IMA was better able to predict events over 
time
84
. Samples were taken at presentation, 3 hours, and 6 hours. With a cut-off of 80 units/mL, 
sensitivity was 70% at 0 hrs, 81% at 3 hours, and 92% at 6 hours, while specificity was poor: 
24%, 11%, and 6%, respectively. Kavsak et al., in a similar study, did not find IMA to be 
predictive of outcomes within 72 hours
85
. In patients resuscitated from cardiac arrest, IMA was 
increased in those that went on to have a poor outcome over those with a good outcome
50
. In that 
study, the IMA level of the good outcome group was not increased over the control group 
(healthy volunteers). An evaluation of IMA relative to outcome at 1 year in patients with acute 
myocardial ischemia observed that the measurement was an independent predictor of death at the 
end of the study period, along with B-type natriuretic peptide concentration, heart failure, and 
age
86
. In 63 patients that underwent cardiac surgery, 10 developed perioperative infarctions; the 
IMA levels of those 10 patients were significantly higher at 3 hours post-operatively than those 
that did not develop infarctions, due to a slower decrease in IMA toward baseline in the infarct 
group
87
.  
Definite limitations have been encountered in the use of IMA in the medical literature. IMA was 
not different between patients with non-acute myocardial infarction, compared with acute 
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myocardial infarction
41
. A study of chest pain patients contained a subset of stroke victims with 
elevated IMA and normal cTnT at presentation
88
, so care must be taken in evaluating patients 
with chest pain and neurological signs, as IMA levels alone are not likely to distinguish these 
groups. Measurement of IMA did not add prognostic value to the Thrombolyis in Myocardial 
Infarction risk score in patients with STEMI that underwent angioplasty
89
. Wudkowska et al. 
failed to show that IMA was able to distinguish between cardiac troponin I positive and negative 
groups, the underlying diagnoses of which were unstable angina and NSTEMI, respectively
90
; 
however, elsewhere, these diagnoses are classified together as non-ST elevation acute coronary 
syndrome (NSTE-ACS)
71
. 
Exercise stress tests are used to evaluate a patient‘s ECG for characteristic changes associated 
with myocardial ischemia that are not present while the patient is at rest. Interestingly, IMA 
levels in myocardial ischemia in the context of exercise stress testing appear to be less consistent 
than in patients at rest. Lee et al. observed that patients that developed ECG changes during 
exercise and had a statistically significant increase in IMA compared to baseline had a large 
ischemic burden, as classified during coronary angiography. Patients that had a positive exercise 
stress test but a negative IMA test (decrease in IMA with exercise) more often had a small 
ischemic burden at angiography; however, there was overlap between groups
91
. Another study 
that similarly evaluated IMA after exercise stress testing, compared with before, did not find a 
difference between the two study groups, those with and without coronary artery stenosis, 
determined at coronary angiography within 1 week of the stress test
92
. Only 14 of the 40 total 
patients had coronary artery stenosis, so the power of the study may have been too low to 
distinguish a difference. Another small study failed to identify a difference in IMA with exercise 
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stress testing
59
. Of 38 patients with chest pain, 15 had myocardial ischemia determined on 
myocardial perfusion scintigraphy. Both the ischemic and non-ischemic groups experienced 
decreased IMA levels (compared with baseline) at peak exercise. The researchers found that 
albumin concentration was the only determinant of IMA, with an increase in albumin (likely due 
to fluid shifts) and a concurrent decrease in IMA
59
. Sbarouni et al. evaluated exercise stress 
testing of 40 patients with previously-diagnosed coronary artery disease; of these, 32 patients had 
undergone percutaneous coronary intervention (angioplasty) or coronary artery bypass surgery
93
. 
The remaining 8 had at least one coronary artery with more than 80% stenosis. Of the total 
patient group, 25 developed ECG changes with exercise (positive result), 14 were negative, and 
1 was excluded due to an equivocal ECG. IMA levels were not significantly different between 
the positive and negative exercise stress tests, but IMA did decrease significantly at peak 
exercise and return to baseline by 60 minutes post-exercise in both groups
93
. An evaluation of 44 
patients that underwent exercise stress testing did not identify a change in IMA levels from 
baseline in either the patients with coronary artery stenosis (n=25) or those with normal arteries 
(n=19)
94
. Contrasting the previously-discussed studies, there was no decrease in IMA with 
exercise in either group. 
In a related study, exercise stress testing in patients with peripheral, rather than coronary, 
vascular disease reveals similar decreases in IMA levels with leg ischemia at peak exercise
95
. 
These values returned to baseline when measured at 60 minutes post-exercise. A study of healthy 
volunteers undergoing forearm ischemia found that IMA levels were decreased at minutes 1, 3, 
and 5 following release of blood pressure cuff; IMA had returned to baseline by 10 minutes post-
ischemia
96
. IMA levels were negatively correlated with albumin concentrations. 
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In situations of exercise, regardless of underlying disease, it may be that the influence of the total 
albumin concentration and the fluid shifts that occur with activity mask significant variations in 
IMA that are caused by the underlying disease. The takeaway is that there is insufficient 
evidence that IMA is a reliable indicator of myocardial ischemia during exercise stress testing.  
Skeletal Muscle 
In addition to the leg and forearm ischemia studies discussed above, IMA has been further 
evaluated with respect to skeletal muscle, exercise, and possible ischemia in healthy volunteers, 
with mixed results. A study of 12 healthy volunteers performing exercise on a plantar flexion 
pedal to induce calf muscle ischemia reported that subjects‘ IMA levels were significantly 
increased immediately following exercise
97
. IMA levels returned to baseline by 30 minutes after 
exercise, and a negative correlation was noted between albumin and IMA. There was no 
association found between lactate and IMA. In another report, a comparison was made between 
the IMA levels of well-trained professional cyclists and sedentary controls; participants had last 
exercised 12 to 24 hours prior to sampling for the study. The IMA levels of the cyclists were 
found to be slightly but significantly elevated over that of the sedentary controls, while BNP 
levels were decreased
98
. Lippi et al. evaluated the effect of high-workload and medium-workload 
endurance training by fit athletes, compared with light exercise by sedentary individuals, on IMA 
levels. They observed that athletes performing high-workload training had increased IMA levels, 
while they did not differ between athletes performing medium-workload exercise and sedentary 
individuals performing light exercise
99
. A study of trained male athletes performing submaximal 
exercise failed to show any change in IMA from baseline. In another study, samples were taken 
from 19 marathon runners pre-race, immediately post-race, and 24-48 hours post-race
2
. Six 
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runners had slight increases in IMA at baseline. IMA levels were decreased significantly from 
baseline immediately following the race, while a significant increase in IMA above both baseline 
and the immediate post-race levels was reported for the participants at the 24-48 hour mark. The 
researchers suggested delayed skeletal muscle ischemia or gastrointestinal ischemia as potential 
causes for this variability
2
. 
Evaluation of IMA in skeletal muscle ischemia in several medical scenarios has also been 
described. IMA appeared to be useful in monitoring the viability of muscle flaps in experimental 
models of rabbits, with increases observed in animals with flaps in which the vascular pedicles 
supplying the area had been severed
100
. This same group performed a similar experiment using 
skin flaps in rats, but noted that IMA levels did not correlate with necrotic flap areas at 6 hours 
or 1 week post-operatively
101
.  
Regarding orthopedic surgery, two studies have been performed. The first, by Refaai et al., 
measured IMA levels in patients before, 15 minutes after, and before discharge (1.0 to 3.5 hours 
after surgery) in patients undergoing arthroscopic knee surgery with a leg tourniquet. IMA was 
increased both at 15 minutes post-operatively and prior to discharge. Albumin concentration was 
also decreased, which may be the underlying cause for the increase in IMA observed
31
. The 
second study evaluated IMA levels, along with other cardiac biomarkers NT-proBNP, 
myoglobin, and CK-MB, in patients undergoing significant orthopedic surgery (hip arthroplasty, 
knee arthroplasty, or spine stabilization)
102
. IMA was increased at 4 and 72 hours post-
operatively, while BNP was increased at 72 hours post-op. Myoglobin and CK-MB were 
increased at 4 hours post-operatively but were trending downward at 72 hours. The authors 
concluded that there was concern for cardiac injury in patients without pre-operative cardiac 
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abnormalities undergoing surgery and posited that the IV infusion of large fluid volumes may 
produce subclinical cardiac stress
102
.  
Embolic Disease 
Given the potential value of IMA in identifying or ruling out ischemic disease, this analyte has 
also been evaluated in other embolic diseases, including cerebrovascular accidents and 
pulmonary thromboembolism. Mentioned previously, Talwalkar et al. found that several stroke 
patients in their study group displayed increased IMA
88
. Another study examined the use of 
IMA, as well as a calculated IMA index, comparing stroke victims to non-stroke patients
103
. 
They found that both IMA and IMA index were increased in stroke victims, compared with 
controls but that there was little overlap between groups when using the IMA index
103
. Gunduz 
et al. found that IMA was increased in patients with intracranial hemorrhage, brain infarction and 
subarachnoid hemorrhage compared with controls. In that study, IMA was higher in brain 
infarction patients compared with subarachnoid hemorrhage, but it could not distinguish brain 
infarction from intracranial hemorrhage
104
. Abboud et al. found that IMA was correlated with the 
National Institute of Health Stroke Scale in patients with brain infarction and was able to 
distinguish brain infarction and intracranial hemorrhage from transient ischemic attack and 
epileptic seizures in patients with neurologic deficits; however, IMA was not able to distinguish 
brain infarction from intracranial hemorrhage in the study group
105
. Another group similarly was 
unable to use IMA to differentiate intracranial hemorrhage from stroke; additionally, IMA was 
not useful in predicting short-term prognosis in the study group
106
. 
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Pulmonary thromboembolism (PTE) is another area of potential use for IMA. Turedi et al. 
published three sequential papers evaluating IMA in pulmonary embolism. The first, in 2007, 
determined that IMA was higher in people with pulmonary thromboembolism compared with 
healthy controls and that the marker may be useful in excluding pulmonary embolism
107
. In 
2008, the group reported that, in patients suspected to have PTE, IMA was higher in patients 
with PTE compared with those without, as determined by imaging procedures. Additionally, a 
comparison of IMA to D-dimer concentration in those patients with pulmonary embolism 
revealed that tests had similar performances (IMA sensitivity = 93%, specificity 75%; D-dimer 
sensitivity = 98.9%, specificity 62.7%) and that IMA was a viable alternative to D-dimer testing 
in suspected PTE patients
108
. Finally, a paper published in 2009 reviewed IMA findings in an 
experimental model of pulmonary embolism in New Zealand rabbits
33
. This experiment utilized 
4 groups of rabbits: group 1 was made up of control animals, group 2 had ligation of the iliac 
vein to simulate deep venous thrombosis, group 3 had ligation of the iliac vein and induction of 
PTE by injection of clot material, and group 4 had only PTE. Samples were taken pre-
operatively at time 0 and then again at 1, 3, and 6 hours after thrombosis. The IMA levels in the 
animals with PTEs were elevated by the 1 hour mark and continued to climb, while animals with 
deep venous thrombosis alone and control animals remained near baseline. There was no 
difference between groups 1 and 2 or between groups 3 and 4
33
. In the discussion of this paper, 
the authors note that deep venous thrombosis is frequently associated with pulmonary 
thromboembolism and that D-dimer concentrations are typically elevated in each condition
33
. 
IMA may be a useful adjunct in assessing a patient with deep venous thrombosis for a concurrent 
PTE but further work is required.  
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Mesenteric, Ovarian, and Testicular Ischemia 
Evaluation of mesenteric ischemia has primarily occurred in experimental models with 
laboratory animals, though one evaluated IMA in human patients with thromboembolism of the 
superior mesenteric artery (SMA) and found that it was elevated, with very little overlap with the 
healthy control group
109
. Two studies found elevations in IMA following experimental ligations 
of the SMA in rats and rabbits, which continued to increase significantly with time
110,111
. 
However, another study in rats failed to find a difference in IMA levels between animals with 
vascular ligations and those that only had sham surgeries
12
.  
IMA levels were significantly increased in rat models of ovarian torsion
11
, and a related study 
noted that administration of the antifungal clotrimazole, which is a potent free radical scavenger, 
to rats undergoing ovarian torsion decreased the magnitude of increase in IMA, 
malondialdehyde, and total oxidant status
55
.    
Testicular torsion has also been assessed. Three studies using rat models observed significant 
increases in IMA levels with testicular torsion
9,10,56
, while one found that the increase was 
blunted by the administration of N-acetylcysteine
56
. The latter study also observed that the 
degree of IMA increase correlated with an increasing histopathology score of the damage in the 
testicular tissue. 
Diabetes Mellitus 
There is evidence in the medical literature that ongoing oxidative damage secondary to 
hyperglycemia occurs in diabetic patients, which precedes overt diabetic complications
112
. 
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Assessment of IMA in patients with diabetes has not only evaluated the levels of IMA in these 
people compared with healthy controls, but several studies have also assessed the relationship 
between IMA and more biochemical values than many other studies have attempted, including 
indicators of inflammation and oxidative damage, such as malondialdehyde, a marker of lipid 
peroxidation
113
. 
A study by Kaefer et al. noted that IMA levels in patients with type 2 diabetes mellitus (T2DM) 
were significantly higher when compared with controls. In addition, IMA was weakly correlated 
with fasting glucose concentrations and high-sensitivity C-reactive protein (hs-CRP). The 
correlation between IMA and glycated albumin approached significance (p=0.0561), but there 
was no relationship between IMA and triglycerides, creatinine, total cholesterol, HDL 
cholesterol, or albumin in the data
5
. However, another study of patients with T2DM and diabetic 
ketosis (DK) failed to identify correlations between IMA and any of the biochemical data 
collected, including CRP, though IMA was elevated in both T2DM and DK patients and was 
significantly different between T2DM and DK
47
. The area under the curve for distinguishing DK 
was 0.917, with a sensitivity of 87.0% and specificity of 85.7% at an optimum cut-off, and the 
researchers concluded that IMA was an independent risk marker for DK. Patients in that study 
were excluded if they had other inflammatory conditions or ECG abnormalities. Piwowar et al. 
noted that not only was IMA increased in T2DM compared with controls, but there was a 
statistically significant difference between patients with poor glycemic control and those with 
good glycemic control
3
. In an assessment of IMA in type 1 diabetes mellitus (T1DM) patients, 
IMA was found to be increased in those with type 1 diabetic ketosis compared with 
uncomplicated T1DM and controls
4
. CRP was also increased in that group. IMA, CRP, and 
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blood glucose all decreased following insulin treatment. Researchers in this study also concluded 
that IMA was an independent risk marker for diabetic ketoacidosis
4
.  
Several studies have evaluated IMA in diabetic patients with confirmed peripheral arterial 
disease secondary to their DM. The study by Piwowar subdivided the T2DM group into 
―microangiopathy‖, ―macroangiopathy‖, and ―both‖ groups but were unable to find a significant 
difference between any
3
. However, Ma et al. observed that DM patients diagnosed with 
peripheral arterial disease via the ankle-brachial index had higher IMA levels than DM without 
vascular disease
4
. Increased IMA levels in patients with diabetic retinopathy compared with DM 
patients without retinopathy is surmised to be evidence of retinal ischemia and oxidative stress-
related neovascularization
51
. These patients also had higher concentrations of malondialdehyde, 
though IMA was more sensitive for retinopathy.  
Obesity 
Though often present with other diseases, obesity is considered a chronic disease in its own right 
and is associated with an inflammatory element
114
. With this background, some studies have 
evaluated IMA levels in obese individuals, measuring it concurrently with inflammatory 
markers, and assessing for correlations with body mass index (BMI). While a study of diabetic 
patients failed to find a correlation between BMI and IMA
46
, two other reports did note links. 
One group identified a correlation between IMA and BMI, though there was considerable 
overlap between the BMI groups
32
. Those with a BMI classified as ―obese‖ had higher IMA, 
malondialdehyde, and fasting glucose concentrations, while HDL cholesterol was decreased, in 
comparison with individuals with a ―healthy‖ BMI. There was no difference in total cholesterol, 
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LDL cholesterol, or triglycerides in the obese versus healthy groups
32
.  In a later study, this same 
group noted that BMI was correlated not only to IMA, but also to IL-6, nitrate/nitrite levels (as a 
marker of nitric oxide status), and urinary albumin
6
. IMA, IL-6, and urinary albumin were all 
increased in obese individuals, while nitrate/nitrite levels were decreased. The authors 
considered this a marker of endothelial dysfunction in the study, and the increased urinary 
albumin may indicate some renal dysfunction
6
, so it is likely that multiple factors are at work in 
these patients to increase the IMA. Finally, a study of overweight or obese post-menopausal 
women observed that IMA and the IMA: albumin ratio were increased in obese women 
compared with women of a healthy weight but did not differ from women with coronary artery 
disease (who had a range of BMI from healthy to overweight)
115
. IMA was correlated with 
hsCRP and insulin concentrations, consistent with reports in diabetic patients, and was 
negatively correlated with albumin concentration
115
.  
Renal Disease and Effects of Dialysis 
Chronic renal disease often results in anemia due to decreased renal production of erythropoietin, 
which has the potential to result in tissue hypoxia. A study of 17 patients with chronic kidney 
disease (CKD) and associated anemia were compared with 19 healthy controls
61
. IMA was 
increased in the anemic CKD patients, and IMA was correlated with hemoglobin, lactate, and 
creatinine. Albumin concentration was reported to be significantly lower in the CKD group, but a 
correlation with IMA was not reported
61
. In combination with an elevated cTnI, an elevated IMA 
was predictive of mortality, but it was not an independent predictor of mortality in patients with 
end stage renal disease
116
.  
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The majority of the studies concerning chronic kidney disease focus on the effects of 
hemodialysis on IMA. A study by Malindretos found that IMA, hsCRP, IL-6, and TNF-alpha all 
increased in post-dialysis samples, suggesting that hemodialysis induces inflammatory 
mediators
117
. Another study identified elevated IMA levels pre-hemodialysis in 6 of 45 patients 
with impaired renal function; samples were adjusted for hemoconcentration in the following 
manner: adjusted post-dialysis value of marker = unadjusted post-dialysis value of marker x (pre-
dialysis albumin/post-dialysis albumin)
118
. Hemodialysis itself caused a mean increase in IMA of 
38% across the group in post-procedure sampling. Abarello et al. found that IMA and protein 
carbonyl groups (used as a marker of protein oxidation) both increased in patient samples 
following hemodialysis, with IMA correlated to protein carbonyls, and suggested that the 
increase in IMA was due to oxidative stress that occurred with the dialysis procedure
54
. 
However, a study that used the IMA : albumin ratio to account for hemoconcentration observed 
no difference in pre- and post-hemodialysis levels, nor did they note a difference between 
synthetic and cellulose-based dialysis membranes
119
. 
Other Conditions 
A variety of other conditions and diseases have been found to have increased levels of IMA, with 
ischemia and/or oxidative damage being blamed as underlying causes.  
Normal pregnancy has increased IMA, with statistically significant additional elevations 
observed in those with complicated deliveries, women with pre-eclampsia, intrauterine growth 
restricted pregnancies, and women with recurrent pregnancy loss in the first trimester
60,120–122
. 
One study did not identify a difference in IMA levels in women with pre-eclampsia
34
.  
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Children with chronic liver disease have been observed to have higher IMA and IMA: albumin 
ratios (IMAR), which correlated with pediatric end-stage liver disease score and fibrosis score
123
. 
IMAR had some ability to predict the presence of severe fibrosis (sensitivity = 84%, specificity = 
70%, with an optimal cut-off). Increased morbidity and/or mortality was found with an IMAR 
greater than 0.156, and IMAR had a sensitivity of 83% and specificity of 82% with an optimal 
cut-off to predict the need for transplant and/or death
123
. Chen et al. found that IMA and IMAR 
were increased in adult patients with chronic hepatitis or cirrhosis and that both were associated 
with measures of liver function (indocyanine green retention, total bilirubin concentration, and 
total antioxidant capacity)
66
. IMAR was associated with the model for end-stage liver disease 
(MELD) score, which is used to rank the transplant recipient waiting list. Interestingly, a 3 day 
intravenous infusion of human albumin did not significantly change the albumin concentration, 
IMA, or IMAR
66
. 
Among neoplasms, a few have been evaluated with respect to IMA. In two separate publications 
by the same group, children with soft tissue sarcomas or neuroblastomas were studied
124,125
. It 
was revealed that IMA increased in the patients when grouped by their respective diagnosis or as 
a single neoplasia group and that IMA increased during treatment
124
. Children with poorly-
responding cancer had lower superoxide dismutase and glutathione peroxidase, but it does not 
appear that the researchers tried to correlate IMA with these measurements of antioxidants
125
. 
Patients with polycythemia vera had increased IMA, and the researchers speculated that this was 
an indication of ischemia secondary to hyperviscosity syndrome
126
. Finally, men with benign 
prostatic hyperplasia had statistically significant elevations in IMA over controls, while men 
with prostatic carcinoma had increased IMA levels that did not reach significance
45
. 
29 
 
Other conditions that have been found to have statistically significant elevations in IMA include 
psoriasis, severe sepsis, systemic sclerosis, primary angle closure glaucoma, hyperthyroidism, 
hypothyroidism, and beta-thalassemia major
49,52,53,127–130
. Evaluation of IMA levels in various 
pleural effusions observed differences between transudates and exudates, while serum IMA 
levels were comparable between groups
131
. This same study also noted some statistically 
significant differences between underlying disease etiologies for the effusions (cancer, 
tuberculosis, pulmonary thromboembolism), but a great deal of overlap was also identified. 
Finally, an experimental model of abdominal compartment syndrome (organ dysfunction 
secondary to increased intra-abdominal pressure), in which rabbit abdominal cavities were 
insufflated to 25 mmHg, observed that animals insufflated for 60 minutes had stastically 
significant elevations over animals insufflated for 15 and 30 minutes, but not the 30 minute 
group
52
.  
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CHAPTER 3 
MATERIALS AND METHODS 
Objectives: 
1) Validate the serum cobalt-binding assay for use in cats. 
2) Evaluate serum cobalt binding in healthy and diseased cats. 
3) Identify specific conditions or diseases that alter serum cobalt binding in cats.  
Hypotheses: 
1) Cobalt binding occurs in feline serum as reported in non-feline serum. 
2) Feline serum cobalt binding reflects the serum albumin concentration and correlates with 
serum concentrations of other albumin-binding compounds. 
3) Cobalt binding by feline serum is affected by diseases associated with increased free 
radical production, including tissue ischemia and systemic inflammation. 
Serum Cobalt-Binding (SCB) Assay 
The colorimetric assay used in this study is a modification of the original protocol published by 
Bar-Or et al. It uses parallel wells to measure the light absorbance with maximum and minimum 
cobalt-binding and normalizes for background absorbance of each sample. The theory of the 
SCB assay is that Co
+2
 bound to albumin is unavailable for reaction with dithiothreitol. Unbound 
cobalt ions however are free to react with dithiothreitol, resulting in a colored product that 
absorbs light at 450 nm
23
. It is performed as follows: 
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1. Prepare CoCl2 by dissolving 0.28 grams (g) CoCl2·6H20 (Sigma, St. Louis, MO) into 100 
mLs deionized (DI) water.  
2. Prepare DL-dithiothreitol (DTT) by dissolving 0.13 g DL-DTT (Sigma, St. Louis, MO) 
into 100 mLs DI water.  
3. Add 47.5 L serum to duplicate 300 L wells (―Well #1‖ and ―Well #2‖) of a clear 
bottom 96-well microtiter plate (Thermo Fisher Scientific, Rochester, NY).  
4. Add 2.5 L CoCl2 solution to Well #1. 
5. Shake the plate for 9 seconds at 20 Hz and 1 mm rotation (setting #3) on an Opsys MR 
plate reader (Dynex Technologies, Inc., Chantilly, VA) and measure the ―preincubation‖ 
(Pre Inc) light absorbance at 450 nm (A450) immediately.  
6. Incubate the plate for 10 minutes at 37C.  
7. Add 2.5 L CoCl2 to Well #2, followed immediately by 12.5 L DTT to both wells.  
8. Shake the plate for 2 minutes at 200 RPM on an IKA-Vibrax-VXR orbital shaker (IKA 
Works, Inc., Germany).  
9. Shake the plate for 9 seconds on the plate reader, setting #3, and measure the ―post 
incubation‖ (Post Inc) A450 of Wells #1 & #2.  
 
Percent cobalt binding (%CB) is calculated as follows: 
[[(Post Inc Well #2 — Pre Inc Well #1) — (Post Inc Well #1 — Pre Inc Well #1)] ÷ [Post Inc 
Well #2 — Pre Inc Well #1]] X 100% 
This formula utilizes the Post Inc Well #2 as the control for color change generated by the cobalt 
added in step 7 of the protocol, which is unbound by albumin and available to react with DTT, 
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while removing the confounding effect of the cobalt itself within the solution (Pre Inc Well #1). 
The results of Post Inc Well #1 represent the color change generated by the remaining unbound 
cobalt reacting with DTT following the 10 minute incubation period. The residual cobalt reading, 
reported in absorbance units (ABSU), is subtracted from the total cobalt reading (also in ABSU) 
to give an estimation of the cobalt that is bound by albumin. This amount is divided by the total 
cobalt ABSU to give a percentage of the total cobalt that is bound to albumin.  
Post Inc Well #2: Represents approximately 0% cobalt binding by albumin and is the color 
change caused by maximum reaction of cobalt with DTT. 
Pre Inc Well #1: Represents the baseline color of the solution after full addition of cobalt without 
DTT and without albumin binding. 
Post Inc Well #1: Represents the color change obtained by DTT binding to any residual cobalt 
present in the solution after albumin is allowed to bind cobalt. 
(Post Inc Well#2 — Pre Inc Well#1): Represents the color change from unbound cobalt binding 
DTT while removing any interference by addition of the cobalt itself to the solution. 
(Post Inc Well#1 — Pre Inc Well#1): Represents the color change caused by residual cobalt 
binding DTT after albumin is allowed to bind cobalt. 
The SCB assay was routinely run in duplicate on each serum sample and the %CB was reported 
as the average of the duplicate results.  
Sample Collection 
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Clinical case samples 
Animal use in this study was approved by the University of Illinois Institutional Animal Care 
and Use Committee. From June 2011 through December 2011, sera from cats that presented to 
the University of Illinois Veterinary Teaching hospital for any reason were considered for 
inclusion into this study. The serum samples had been submitted to the clinical pathology 
laboratory for clinical biochemical analysis in the course of the medical assessment. All testing 
performed on these samples was at the discretion of the clinician on each case and no attempt 
was made to seek out cats of any particular disease or status for this study. Submitted samples for 
which at least 250 μL of serum remained following completion of the requested testing were 
further considered for inclusion. Samples that had a 1+ or greater lipemic index or 3+ or greater 
hemolytic index as measured on the serum chemistry results from an AU680 Chemistry 
Analyzer (Beckman Coulter, Inc., Brea, CA) were excluded from the study. The samples were 
stored frozen first in a frost-free freezer at -7 to -17
o
C for 2 to 3 weeks before transfer to a -20
o
C 
freezer for up to 3 months before measurement of %CB.  
Samples for validation of SCB stability 
Five mLs of whole blood was collected into a plain glass tube, via jugular or medial saphenous 
venipuncture, from 3 clinically healthy cats that were volunteered by their owners. Samples were 
allowed to clot at room temperature for 30 minutes, after which they were centrifuged and the 
serum transferred into plain glass tubes and frozen at -20
o
C following storage at room 
temperature for set time periods (see below). The serum was used to test the stability of serum 
cobalt binding over time of storage at room temperature.  
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Laboratory Validation of the Serum Cobalt-binding (SCB) Assay 
Randomly-chosen serum samples were used for test validation experiments. Run-to-run test 
imprecision was assessed using three serum samples that were divided into 12 separate aliquots 
and stored at -20C. The SCB assay was performed 12 times using one aliquot of each sample, 
and the mean, standard deviation (SD), and percent coefficient of variation (CV) calculated for 
each. The within-run test imprecision of the SCB assay was tested using a pooled feline serum 
sample 24 times in a single run. The day-to-day test imprecision was performed by running the 
SCB assay on five days using aliquots of a pooled serum sample that were thawed just prior to 
assay. Linearity upon serial dilution (1:2, 1:4, and 1:8) of the SCB assay was tested in 3 feline 
serum samples that were serially diluted with pH 7.2 phosphate buffered saline (PBS; Sigma, St. 
Louis, MO). The biological variation of serum cobalt binding was evaluated in 2 cats that had 
repeat serum samples submitted to the Clinical Pathology Laboratory on different days.  
Pooled serum was used to assess the effect of interfering substances. Hemolysis was induced by 
addition of 1 mL of PBS to a residual clot from one of the cat samples, followed by freezing and 
thawing; after this, the sample was thoroughly agitated, centrifuged, and the supernatant fluid 
removed to a new plain tube. Dilutions with pooled serum were made to create 1+, 2+, 3+, and 
4+ hemolytic indices, as follows: 
 One mL of the supernatant was added to 1 mL of pooled serum. From this 1:2 dilution, 
dilutions 1:4, 1:8, 1:16, and 1:32 were made.  
 From this, further dilutions were made and tested to find the mixtures to correlate with 1+ 
through 4+ hemolytic index on the AU680 chemistry analyzer.  
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o Addition of 100 μL of the 1:32 dilution to 900 μL of pooled serum resulted in a 
1+ hemolytic index. 
o Addition of 100 μL of the 1:16 dilution to 900 μL of pooled serum resulted in a 
2+ hemolytic index. 
o Addition of 75 μL of the 1:4 dilution to 900 μL of pooled serum resulted in a 3+ 
hemolytic index. 
o Addition of 100 μL of the 1:2 dilution to 900 μL of pooled serum resulted in a 4+ 
hemolytic index. 
This was followed by determination of the %CB of each respective dilution and the undiluted 
serum.  
Lipemia was simulated by the addition of Intralipid 20% (Fresenius Kabi, Uppsala, Sweden, for 
Baxter Healthcare Corporation, Deerfield, IL) to pooled serum to create 1+, 2+, 3+, and 4+ 
lipemic indices on the AU680 chemistry analyzer, as follows: 
 One mL of Intralipid 20% was added to 1 mL of pooled serum. From this 1:2 dilution, 
dilutions 1:4, 1:8, 1:16, and 1:32 were made.  
 From this, further dilutions were made and tested to find the mixtures to correlate with 1+ 
through 4+ lipemic index on the AU680 chemistry analyzer.  
o Addition of 100 μL of the 1:32 dilution to 900 μL of pooled serum resulted in a 
1+ lipemic index. 
o Addition of 100 μL of the 1:16 dilution to 900 μL of pooled serum resulted in a 
2+ lipemic index. 
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o Addition of 100 μL of the 1:8 dilution to 900 μL of pooled serum resulted in a 3+ 
lipemic index. 
o Addition of 100 μL of the 1:2 dilution to 900 μL of pooled serum resulted in a 4+ 
lipemic index. 
This was followed by measurement of the %CB in the respective lipemic samples.  
Icterus was simulated by adding bilirubin conjugate (EMD Biosciences, Inc., La Jolla, CA) to 
pooled feline plasma, as follows: 
 Five mg of bilirubin conjugate was reconstituted into 500 μL of distilled water for a 10 
mg/mL solution. 
 A 1:2 dilution was made by adding 500 μL of bilirubin solution to 500 μL of pooled 
serum. From this, dilutions of 1:4, 1:8, 1:16, and 1:32 were made. 
o Addition of 20 μL of the 1:2 dilution to 480 μL of pooled serum resulted in a 10.5 
mg/dL solution. Actual concentration was 8.9 mg/dL at analysis. 
o Addition of 20 μL of the 1:4 dilution to 480 μL of pooled serum resulted in a 5.7 
mg/dL solution. Actual concentration was 4.3 mg/dL at analysis. 
o Addition of 20 μL of the 1:8 dilution to 480 μL of pooled serum resulted in a 2.9 
mg/dL solution. Actual concentration was 2.2 mg/dL at analysis. 
o Addition of 20 μL of the 1:16 dilution to 480 μL of pooled serum resulted in a 1.4 
mg/dL solution. Actual concentration was 1.2 mg/dL at analysis 
o Addition of 20 μL of the 1:32 dilution to 480 μL of pooled serum resulted in a 0.7 
mg/dL solution. Actual concentration was 0.7 mg/dL at analysis. 
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o Addition of 20 μL of pooled serum to 480 μL of pooled serum was performed for 
a ‗zero‘ sample. Actual concentration was 0.2 mg/dL at analysis. 
The total bilirubin concentration of each sample was measured on the AU680 Chemistry 
Analyzer. The values ranged in six samples from 0.2 mg/dL to 8.9 mg/dL. The measured icteric 
index of the sample with an 8.9 mg/dL total bilirubin concentration was 2+.  
Fresh serum samples were divided into eight 150 μL aliquots for assessment of room 
temperature stability. Aliquots were labeled as 0 hr, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, 24 hr, and 48 hr 
and left at room temperature for the listed time periods. At each time point, the respectively-
labeled aliquot was placed into a -20
o
 C freezer until batch assay, which was performed within 1 
week. 
Freeze/thaw experiments were performed on waste serum from three freshly collected samples 
submitted for serum biochemistry panels to the Clinical Pathology Laboratory. Excess serum 
was divided into 3 equal aliquots, and labeled as ―0‖, ―1‖, and ―2‖ (two samples) or ―1‖, ―2‖, and 
―3‖ (one sample). Samples labeled as ―0‖ were assayed immediately to provide a baseline. 
Samples labeled as ―1‖, ―2‖, or ―3‖ were frozen at -20oC and allowed to completely thaw at 
room temperature 1, 2, or 3 times before assay.  
Retrospective Evaluation 
Retrospective clinical information was obtained from the medical record of each of the 176 
cases, including the signalment, and time-matched hematology, serum chemistry, and urinalysis 
data. Other clinical data was collected if available and included total T4 (n=131), prothrombin 
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time (4), activated partial thromboplastin time (4), urine protein: creatinine ratio (13), 
reticulocyte count (3), fibrinogen (1), fructoasmine (6), and pre- and post-prandial bile acids (n = 
1 and 2, respectively). Analytes were selected for statistical analysis based on major findings 
from the human literature. Red blood cell count, hemoglobin concentration, hematocrit, white 
blood cell count, absolute leukocyte counts, total protein, albumin, globulins, total calcium, 
ionized calcium, alkaline phosphatase activity, total bilirubin, triglycerides, cholesterol, lactate, 
and pH were selected for statistical analysis. Complete blood counts were performed on a CELL-
DYN 3700 (Abbott Laboratories, Abbott Park, IL). Some cats had heparinized blood samples 
analyzed for emergency mini-panels on a Stat Profile® Critical Care Xpress machine (Nova 
Biomedical Corp., Waltham, MA).  
The clinical diagnosis of each case was determined from the medical record. The cases were 
grouped by disease into the following categories: cardiomyopathy, dental disease, endocrine 
disease (primarily hyperthyroidism and diabetes mellitus), bone fractures, infectious disease, 
neoplasia, wellness visit, multiple diseases, other diagnoses, and ―open‖ diagnosis. If possible, 
cases were subclassified as inflammatory or noninflammatory based on the final diagnosis and 
leukogram findings. Cases were considered noninflammatory if the leukogram had absolute 
leukocyte indices within reference interval and no evidence of toxicity or ―rare‖/‖few‖ toxic 
changes. Patients were classified as inflammatory, 1) if a mature neutrophilia was present with 
an absolute lymphocyte count within reference limits, 2) if the absolute band neutrophil count 
was greater than the upper reference limit, or 3) if 1+ or greater cell toxicity was noted on 
manual blood smear evaluation, or some combination of these criteria was present. Type of 
toxicity was not considered, and cases with ―rare‖ or ―few‖ toxic changes were not included 
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unless criterions 1 or 2 were also met. Though normal cats can have signs of toxic changes on 
blood smear, particularly Dohle bodies, 1+ toxicity was selected as the lower limit for inclusion 
for higher sensitivity. Leukograms with features that did not fit these parameters were considered 
equivocal, and data from these patients were not included in the statistical analysis comparing 
inflammatory and nonflammatory %CB values. If the final diagnosis in the file was not 
consistent with an inflammatory disease, but the patient showed the above described signs of 
inflammation, it was still included in the inflammatory group. Samples in which the final 
diagnosis was an inflammatory condition but an inflammatory leukon was not present were 
considered equivocal. 
Statistical Analysis of the Retrospective Study Results 
The distribution of the data was evaluated using the Shapiro-Wilkes test, skewness, kurtosis, and 
q-q plots. Data that was not normally distributed was log transformed for parametric testing. 
Normally distributed data is reported by the mean, SD, and minimum-maximum (Min-Max), 
while non-normally distributed data is reported by the median, 25th-75
th
 percentiles, and min-
max. A Mann-Whitney U test was used to determine if cobalt levels differed by the 
presence/absence of inflammation. A general linear model was used to determine if disease 
status, sex, or breed influenced %CB. Pearson‘s correlation was used to determine if there was 
an association between cobalt and the various hematology and biochemistry data. When the 
assumption of normality could not be met through transformation, Spearman‘s rho correlation 
analysis was done. Multiple linear regression was used to determine if any of the hematology or 
biochemistry variables found to be correlated to cobalt could be used to predict cobalt values. A 
stepwise method was used to develop the model. A p<0.05 was used to determine statistical 
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significance. SPSS 19.0 (SPSS Inc., Chicago, IL) and GraphPad Prism 5.0 (GraphPad Software, 
Inc., La Jolla, CA) were used to analyze the data.   
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RESULTS 
Validation 
Within-run precision ranged from 2.61% to 4.04% over 24 runs (Figure 3). Run-to-run precision 
ranged from 2.90% to 4.37% over 30 runs (3 samples, 10 runs each) (Figure 4). Day-to-day 
precision was 3.46% over 5 days (Figure 5). Limited biological variation assessment showed 
clinically insignificant changes (Figure 6). Results from room temperature and freeze-thaw 
stability experiments were examined for clinically significant alterations in the percent cobalt 
albumin binding (defined as a change from baseline greater than 10%). Room temperature 
stability testing revealed some variability. One cat‘s sample had an increase of almost 16% at 4 
hours after sample collection, while the two others had increases of 1% and just over 10%, 
respectively. The first cat, in fact, had an increase of almost 12% by 1 hour post-collection, 
which was not observed in the other two (Figure 7). This cat‘s sample was drawn and assayed on 
a different day than the other two. All samples tested appeared stable with one freeze-thaw cycle, 
and 2 of 3 remained stable for up to three cycles (Figure 8). Even mild lipemia (lipemic index of 
1+) was found to falsely decrease the percent cobalt binding, as did significant hemolysis 
(hemolytic index 3+ or greater; Figure 9A). Icterus, tested to 8.7 mg/dL bilirubin, did not have a 
significant effect on the cobalt binding measurements (Figure 9B). Percent cobalt binding 
appeared linear upon dilution (Figure 10).  
Retrospective Evaluation 
Based on the results of the validation studies, serum samples were excluded from analysis if they 
had a 1+ or greater lipemic index or were visibly lipemic. Samples were also excluded if 3+ or 
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greater hemolytic index was reported. Approximately 250 μL of sample was required to run the 
assay in duplicate, and, as such, samples of insufficient volume were excluded. Serum from 176 
of the 374 samples obtained over the 6-month collection period was of acceptable quality and 
volume for inclusion in this study. 
Of 176 cases, 150 had CBCs and 135 had serum biochemistry panels performed. Twenty-three 
had mini-panels performed on the Stat Profile® Critical Care Xpress machine. Other tests 
performed included renal biochemical profile, hepatic biochemical profile, urinalysis, total T4, 
urine protein: creatinine ratio, prothrombin time, activated partial thromboplastin time, pre- and 
post-prandial bile acids, fibrinogen and fructosamine. 
There were 69 (39.2%) spayed female cats, 104 (59.1%) neutered males, and 3 (1.7%) intact 
female cats used in this study, representing 13 different breed groups (Figure 11). There were 
108 domestic shorthair cats, 20 domestic longhair cats, 18 mixed breed cats, 10 domestic 
medium hair cats, 9 Maine Coons, 2 Abyssinians, 2 Norwegian Forest Cats, and 1 each of 
Birman, Himalayan, Oriental Shorthair, Ragdoll, Russian Blue, Siamese, and Tonkinese (Figure 
12). 
The median age of the cats in this population was 10.5 years (25
th
-75
th
 percentiles: 7.4-13.3, min-
max: 0.6-20.3). Health status of the cats were classified into 9 different disease states (chronic 
kidney disease, n=15; cardiomyopathy, n=7; dental, n=3; endocrine disease, n=13; fracture, n=3; 
infectious, n=5; multiple diagnoses, n=16; neoplasia, n=47; other, n=9) or characterized as 
having an open diagnosis (n=53) or normal health state (n=5) (Figure 13). Percent cobalt binding 
results for the respective disease groups can be seen in Table 1. Cats with a normal health state 
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were presented for routine wellness examinations and were without abnormalities on history, 
physical examination, complete blood count, serum biochemistry analysis, total T4, or urinalysis; 
their values ranged from 67.11% to 89.82%. 
The median percent cobalt binding (%CB) was 73.9% (25
th
-75
th
 percentiles: 66.2-80.3, min-max: 
34.93-92.37). Cats characterized as having inflammation (n=20) had significantly lower 
(p=0.002) %CB (median: 64.6, 25
th
-75
th
 percentiles: 51.2-76.6, min-max: 42.5-90.94) than cats 
without inflammation (n=22) (median: 77.8, 25
th
-75
th
 percentiles: 72.8-88.7, min-max: 59.0-
90.9) (Figure 14). Cats characterized as having inflammation also had significantly lower 
(p=0.002) albumin concentrations (median: 2.70 g/dL, 25
th
-75
th
 percentiles: 2.125-3.100, min-
max: 1.6-3.7) than cats without inflammation (median: 3.25, 25
th
-75
th
 percentiles: 3.0-3.4, min-
max: 2.6-3.8) (Figure 15). Surprisingly, globulin concentrations were not significantly different 
between the inflammatory and noninflammatory group (p=0.6907).  
Cobalt binding percentages were not found to be significantly different by disease state (p=0.61), 
sex (p=0.82), age (p=0.51), or breed (p=0.83). The cats with the lowest %CB tended to have 
multiple diseases or multiple affected body systems. Cobalt binding percentage was found to be 
correlated with red blood cell count (r= 0.24, p=0.003), hemoglobin (r= 0.29, p=0.0001), 
hematocrit (r= 0.283, p=0.0001), albumin (r= 0.62, p=0.0001), globulins (r= -0.20, p=0.01), total 
calcium (r= 0.27, p=0.001), total bilirubin (r= -0.237, p=0.005), and absolute lymphocytes (r= 
0.16, p=0.05). 
Cobalt binding percentage was not found to be correlated to white blood cell count (p=0.32), 
absolute segmented neutrophils (p=0.25), absolute bands (p=0.75), absolute monocytes (p=0.43), 
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absolute eosinophils (p=0.06), absolute basophils (p=0.86), serum total protein (p=0.86), glucose 
(p=0.10), ALP (p=0.91), cholesterol (p=0.26), triglycerides (p=0.72), corrected calcium 
(p=0.14), ionized calcium (p=0.26), lactate (p=0.27), or pH (p=0.63). The results of the stepwise 
linear regression model only included albumin (R
2
=0.425). The final regression equation was:  
cobalt %=20.8 + 16.84 (albumin).  
When albumin was compared to the same analytes, it was found to be correlated to red blood cell 
count (r=0.3258, p<0.0001), hemoglobin (r=0.4465, p<0.0001), hematocrit (r=0.4339, 
p<0.0001), total calcium (r=0.4634, p<0.0001), absolute neutrophils (r= -0.1615, p=0.0484), 
globulins (r= -0.3197, p<0.0001), total bilirubin (r= -0.2251, p=0.0080), total protein (r= -
0.1557, p=0.0486), and cholesterol (r= 0.1852, p=0.0309). 
Albumin was not correlated with absolute bands (p=0.0527), absolute lymphocytes (p=0.2708), 
WBC (p=0.2983), absolute monocytes (p=0.3674), absolute eosinophils (p=0.4429), glucose 
(p=0.0552), ALP (p=0.1308), triglycerides (p=0.0704), pH (p=0.6921), lactate (p=0.4713), and 
ionized calcium (p=0.5841).  
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CHAPTER 5 
DISCUSSION 
Studies in the human literature report cobalt binding test results as absorbance units or 
absorbance units/volume unit obtained from the colorimetric assay, which are then labeled as the 
IMA levels. We chose to calculate and report our test results as percent cobalt binding (%CB) in 
order to correct for differences in the baseline light absorbances. In our study, a decreased %CB 
implies an increased IMA concentration. No correlations were observed between age, sex, or 
breed and %CB; these signalment factors are not expected to be a concern in selection of study 
populations. Correlations between IMA and sex or age in the human literature were not noted 
during reviews of the literature. 
The test validation experiments revealed that the cobalt binding test, using feline serum, is a 
high-precision assay. Coefficients of variation for run-to-run (10 to 11 runs), within-run (24 
individual runs, 12 paired runs), and day-to-day (5 runs) precision were all less than 5%. This is 
similar to the precision of the Albumin Cobalt Binding  (ACB®) test assessed on the Cobas 
MIRA® analyzer
67
. Limited assessment of biological variation was performed, but, in samples 
collected on two successive days from two patients, very little variation was observed (change 
from baseline of 4.2% and 1.1%, respectively). The assessment of serial cobalt binding in a 
greater number of both healthy and diseased cats, however, would be ideal to confirm a lack of 
biological variation with time. A review of the literature failed to find published results 
evaluating biological variation of IMA in people. Evaluation of the effect of interfering 
substances found that even mild lipemia had a significant effect, while significant hemolysis was 
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needed before negative interference was observed; bilirubin did not appear to significantly 
interfere with the assay, up to an icteric index of 2+. This is similar to reports that used human 
serum. Assessment of interfering substances in human samples in one study found no 
interference with high concentrations of hemoglobin (220.4 μmol/l) or triglycerides up to 7 
mmol/l
67
. That study did find a significant effect from bilirubin; however, this did not agree with 
the assay manufacturer‘s information. Further investigation determined that NaOH that was used 
for the bilirubin solution caused similar interference when added to the serum without bilirubin. 
However, that study did not retest bilirubin interference in another diluent.  
It has been recommended that the albumin cobalt binding test be performed within 2 hours of 
sample collection, with most samples remaining stable at room temperature and 4
o
C up to 4 
hours post-collection
68,69
. This recommendation appears to be secondary to identification of 
statistically significant changes. We elected to look for clinically relevant changes, based on 
clinical experience, in the %CB, which was defined as a 10% or greater change from baseline. 
Stability testing in this study revealed that results are minimally to moderately variable from cat 
to cat, although overall the samples appear to be stable at room temperature for at least 2 hours. 
The sample that had the most variability was drawn and processed on a separate day, and sample 
handling may have affected results. Stability at refrigeration temperatures and with long-term 
freezing was not assessed, but evaluation of IMA stability at room temperature in the human 
literature found mild to moderate increases with storage at -20
o
C
67,68
. Some samples from the 
retrospective portion of our study were likely stored up to 8 hours at room temperature before 
freezing, which may have affected the ultimate %CB value obtained. Since the %CB tended to 
increase with time spent at room temperature, it is possible that samples with decreased %CB 
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were missed. A prospective study with stringent sample handling requirements may uncover 
additional links and stronger correlations.   
As predicted, %CB was found to be correlated with albumin concentration and, in fact, was the 
strongest correlate in the study; a decreased serum albumin concentration is the most significant 
predictor of a decreased %CB. This follows the findings in human medicine, where a decreased 
albumin concentration has been associated with increased IMA values
59,63
. With less circulating 
albumin, less protein is available to bind the finite amount of cobalt added in the test. Correction 
formulas have been proposed, which calculate an ischemia modified albumin index
65,103
, an 
albumin-adjusted IMA
127
, or an IMA-to-serum albumin ratio (IMAR)
66
. The IMA index was 
found to be more sensitive than IMA as a marker for stroke, but found no difference between 
IMA index and IMA in patients with progressive stroke compared with nonprogressive stroke
103
. 
Similarly, the IMA index had slightly improved sensitivity over IMA in detecting acute coronary 
syndrome in people
65
. However, as mentioned earlier, validation for these formulas does not 
appear published. In future studies, care must be taken in interpreting %CB of samples from 
hypoalbuminemic animals, and further investigation into some type of correction formula may 
be interesting. Reliable evaluation of the %CB assay in patients with significant liver, 
gastrointestinal, or renal disease, or any other condition in which the albumin concentration is 
increased or decreased, may prove difficult without the use of some correction factor. 
Correlations were observed between %CB and red blood cells, hemoglobin, hematocrit, 
globulins, total calcium, and absolute lymphocytes. However, albumin was also significantly 
correlated to all of these analytes, with the exception of absolute lymphocytes. Therefore, it is 
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likely that %CB is only independently correlated to absolute lymphocytes. The reason for the 
very weak correlation is uncertain and may be coincidental.  
Total calcium was also correlated with %CB, but ionized calcium was not. The likely 
explanation for this is that approximately 45% of total calcium in blood is albumin bound
13
; if 
albumin is decreased in concentration, then it would be unsurprising that both calcium and %CB 
may be decreased, as well. This connection is further support that the serum cobalt binding assay 
is measuring albumin-bound cobalt, other than non-specific binding to other substances. 
Zapico-Muniz et al. found that IMA was negatively influenced by rising lactate concentrations 
both in vivo and in vitro, at concentrations ranging from 3 to 11 mmol/L, in healthy volunteers 
undergoing experimental forearm ischemia
96
. Falkensammer et al. did not find such a correlation 
in a similar study, but lactate concentrations in that study were below the concentrations reported 
in the other study. We found no correlation between %CB and lactate or blood pH. However, 
only 22 cats in our study had lactate concentrations performed, and only 6 of these had values 
above 3 mmol/L, with the highest at 5.1 mmol/L. It may be that a correlation would have been 
found with higher numbers or more exaggerated increases. 
The hypothesis that %CB will be decreased in cats with inflammatory disease compared with 
cats with noninflammatory disease initially appeared to be supported by the results of our study; 
however, we also noted that the inflammatory group had a lower albumin concentration. Given 
the correlation between albumin and %CB, we suspect that this is the underlying reason. Since 
albumin is a negative acute phase protein, decreases in the face of inflammation are expected. 
Additionally, animals may have conditions that cause a loss of albumin (gastrointestinal, renal) 
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that are also inflammatory. A relationship between %CB and segmented or band neutrophil 
numbers was not identified in this study, but albumin was negatively correlated with segmented 
neutrophil numbers, and the correlation between albumin and band neutrophils approached 
significance. Correlations between IMA and leukocytes do not appear to have been evaluated in 
the human literature. However, correlations between IMA and several markers of oxidative stress 
have been identified. In patients with β-thalassemia major, IMA was correlated with ferritin, 
ferroxidase, malondialdehyde, and transaminases. The authors concluded that the evidence of 
iron-induced oxidative stress was from the continuous blood transfusions needed and increased 
erythrocyte turnover that occurs in these patients
130
. In a study of patients with hypo- and 
hyperthyroidism, IMA was found to correlate positively with C-reactive protein concentrations
49
. 
As discussed previously, several other studies found correlations between IMA and CRP in 
patients with a variety of conditions. While one study in people with systemic sclerosis did not 
find a correlation between IMA and CRP, the researchers did find correlations between IMA and 
carbonyl residues and advanced oxidation protein products, which the authors described as 
indicators of protein oxidation
128
. There is sufficient evidence in the literature in in vitro studies, 
as well as clinical observations, that oxidative damage, likely secondary to inflammatory 
processes, plays a role in the alteration of the cobalt-binding capacity of albumin. 
The vast majority of the studies evaluating IMA in the human medical literature did not measure 
concurrent circulating fatty acid levels at the time of sampling for IMA, but a few studies 
convincingly demonstrate a role of fatty acid binding in the development of IMA
8,43,57
. 
Measurement of fatty acids is not a typical component of chemistry panels in our lab and, 
consequently, this was not measured in any patient in our study. Closer study of free fatty acid 
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concentrations in inflammatory cases is needed, as this may be a significant factor in decreases in 
%CB. It is unknown if multiple influences are at work in the cats in this study in which %CB 
was decreased. 
Unfortunately, the study population had very small numbers of cats in several disease groups, 
including cardiomyopathy and liver disease, and no cats with known thromboembolic disease, all 
of which had been of particular interest in the planning of this study. A prospective study 
recruiting cats with specific diseases of interest in adequate numbers is likely required to fully 
identify a relationship between disease and %CB. 
Several limitations are identified within this study. First, no attempt was made to prospectively 
identify cases. As such, our study population included very few healthy cats to serve as controls, 
and several disease categories in which we had a specific interest (thromboembolic disease, 
cardiomyopathy, and hepatic disease) similarly had disappointing numbers. It may be that 
significant findings were not identified due to a lack of study power. Second, the serum cobalt 
binding assay lacks test standards and controls for independent test validations. We were forced 
to use individual and pooled serum samples from our study population to perform the validation 
experiments. Finally, ischemia, oxidative damage, and fatty acid binding are the main suspected 
factors in the formation of IMA, but the cases used in our study did not have arterial blood gas 
data, malondialedhyde or isoprostane levels, or fatty acid concentrations measured, as these are 
not tests performed routinely in basic blood work in veterinary medicine. However, they could 
be included in prospective studies in the future.  
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Overall, this study found that the serum cobalt binding assay is functional and reliable with use 
of cat serum. Correlations were few and almost exclusively due to the albumin concentration. 
This provides strong evidence that the assay is measuring the amount of cobalt bound to albumin 
within the tested feline serum and helps dispel concerns about cobalt binding to other serum 
components. Future work with this assay should require a prospective study design that targets 
specific diseases of interest, careful sample handling, and evaluation of correction factors or 
formulas for albumin concentrations in patients evaluated, in order to more clearly determine if 
this assay serves a practical purpose in diagnostic medicine.  
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CHAPTER 6 
CONCLUSIONS 
• Cat serum forms complexes with transition metals, such as cobalt, in a manner similar to that 
reported for human serum. 
• Serum cobalt binding can be readily measured in cats with acceptable precision using the 
protocol described. 
• Serum samples intended for use in the cobalt binding assay should be assayed within 4 hours; 
if this cannot be done, samples should immediately be frozen at -20
o
C until time of assay. 
• Serum samples for cobalt binding appear stable with up to 3 freeze-thaw cycles but should be 
minimized. 
• Feline serum cobalt binding is correlated with serum albumin concentration. 
Future Directions 
Prospective studies are needed for further evaluation of this assay and its use. Studies targeting 
cats with inflammatory diseases (such as pancreatitis and cholangiohepatitis), conditions 
associated with oxidative damage (such as diabetes mellitus and diabetic ketoacidosis), and 
ischemic conditions (such as heart failure, thromboembolic diseases, and severe anemia) may be 
of particular value. Assessment of serum cobalt binding in cats with untreated hyperthyroidism, 
euthyroid sick syndrome, and iatrogenic hypothyroidism would also be of interest. Because this 
assay has not been evaluated in common veterinary species, studies targeting other animals 
would be of interest, and the study designs can be positively influenced by what has been learned 
in the current study. Prospective studies with careful sample handling will be of the utmost 
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importance. A prospective study that validates the assay for use in horses and evaluates serum 
cobalt binding in cases of equine colic would be interesting. This study may help to discriminate 
medical from surgical colic cases, particularly those with ischemia secondary to intestinal 
torsion, or have prognostic value in such cases. There are many possible avenues of exploration 
with this assay in future projects involving veterinary species.  
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CHAPTER 7 
FIGURES AND TABLES 
 
 
Figure 1. Comparison of human and feline albumin amino acid sequences. 
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Figure 2. Cartoon representation of the serum cobalt binding assay. When a greater fraction of 
the albumin is ischemia-modified albumin, more free Co(II) molecules are in solution. These 
react with dithiothreitol to produce a color reaction. 
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Figure 3. Within-run precision. Over 24 runs, precision ranged from 4.04% in individual runs to 
2.61% in duplicate (pairs).  
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Figure 4. Run-to-run precision ranged from 2.90% to 4.37% over 30 runs (3 samples, 10 runs 
each).  
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Figure 5. Day-to-day precision was 3.46% over 5 days. 
 
Figure  6. Biological variation between two days from samples from two cats. Cat A 
demonstrated a decrease of 4.2%. Cat B demonstrated a decrease of 1.1%.   
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Figure 7. Serum cobalt binding room temperature stability results, displaying mean and standard 
error bars from three individual cat samples. Aliquots from samples from each cat were assayed 
in duplicate and the results averaged. Mean: 84.55%, median: 85.61%, standard deviation: 
3.311%, standard error: 1.170%.  
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Figure 8. Serum cobalt binding over 1 to 3 freeze-thaw cycles. 
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Figure 9A. Effect of increasing hemolytic index and lipemic index on serum cobalt binding. 9B. 
Effect of increasing concentrations of conjugated bilirubin on serum cobalt binding. 
 
 
61 
 
 
Figure 10. Test of the linearity of the %CB with dilution of feline serum with PBS. Dilutions 
were 1:2, 1:4, and 1:8. 
 
 
Figure 11. Sex distribution of the study population. There were 59.1% neutered males, 39.2% 
spayed females, and 1.7% intact females. 
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Figure 12. Breed distribution of the study population. There were 108 domestic shorthair cats, 
20 domestic longhair cats, 18 mixed breed cats, 10 domestic medium hair cats, 9 Maine Coons, 2 
Abyssinians, 2 Norwegian Forest Cats, and 1 each of Birman, Himalayan, Oriental Shorthair, 
Ragdoll, Russian Blue, Siamese, and Tonkinese 
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Figure 13. Disease distribution of the study population: chronic kidney disease (n=15), 
cardiomyopathy (n=7), dental (n=3), endocrine disease (n=13), fracture (n=3), infectious (n=5), 
multiple diagnoses (n=17), neoplasia (n=47), other (n=9), open diagnosis (n=53), and normal 
health state (n=5).  
 
Disease N Median 25
th
 Percentile 75
th
 Percentile Min Max 
Open 53 74.14 69.13 80.06 46.33 87.25 
Neoplasia 47 72.93 66.17 78.63 40.68 92.37 
Multiple 17 65.15 46.28 79.44 34.93 90.94 
CKD 15 74.64 68.36 81.21 61.92 90.94 
Endocrine 13 74.58 70.33 79.44 59.02 83.73 
Other 9 74.28 62.50 83.86 42.50 90.59 
Cardiomyopathy 7 88.02 78.81 89.08 77.32 90.65 
Infectious 5 67.13 48.18 76.45 43.64 77.78 
Normal 5 73.87 70.38 89.29 67.11 89.82 
Dental 3 63.99 58.72 77.70 58.72 77.70 
Fracture 3 62.53 57.51 80.53 57.51 80.53 
 
Table 1. Disease group %CB data. CKD: chronic kidney disease, Min: minimum, Max: 
maximum. 
 
CKD
Cardiomyopathy
Dental
Endocrine disease
Infectious
Multiple diagnoses
Neoplasia
Other
Open
Normal
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Figure 14. Comparison of serum cobalt binding between cases with evidence of systemic 
inflammation and those without. Noninflammatory: median: 77.8%, 25
th
-7
th
 percentiles: 72.88-
88.7%, min-max: 59.0-90.9%. Inflammatory: median: 64.6%, 25
th
-75
th
 percentiles: 51.2-76.6%, 
min-max: 42.5-90.94%. 
 
Figure 15. Comparison of albumin concentration between cases with evidence of systemic 
inflammation and those without. Noninflammatory: median: 3.25 g/dL, 25
th
-75
th
 percentiles: 3.0-
3.4 g/dL, min-max: 2.6-3.8 g/dL. Inflammatory: median: 2.70 g/dL, 25
th
-75
th
 percentiles: 2.13-
3.1 g/dL, min-max: 1.6-3.7 g/dL.  
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